Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.

Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM.

J Clin Lipidol. 2016 May-Jun;10(3):556-67. doi: 10.1016/j.jacl.2015.12.025. Epub 2016 Jan 6.

2.

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.

Kastelein JJ, Hallén J, Vige R, Fraser DA, Zhou R, Hustvedt SO, Orloff DG, Bays HE.

Cardiology. 2016;135(1):3-12. doi: 10.1159/000445047. Epub 2016 May 4.

3.

Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

Bays HE, Hallén J, Vige R, Fraser D, Zhou R, Hustvedt SO, Orloff DG, Kastelein JJ.

J Clin Lipidol. 2016 Jan-Feb;10(1):181-91.e1-2. doi: 10.1016/j.jacl.2015.10.012. Epub 2015 Nov 14.

PMID:
26892135
4.

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.

Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH.

Lipids Health Dis. 2015 Sep 2;14:98. doi: 10.1186/s12944-015-0100-8.

5.

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.

Clin Ther. 2013 Sep;35(9):1400-11.e1-3. doi: 10.1016/j.clinthera.2013.07.420. Epub 2013 Aug 30.

PMID:
23998969
6.

Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.

Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, Zhou R, Orloff DG.

Clin Pharmacol Ther. 2013 Apr;93(4):352-9. doi: 10.1038/clpt.2013.10. Epub 2013 Jan 18.

7.

Regulatory considerations in the development of high-density lipoprotein therapies.

Orloff DG.

Am J Cardiol. 2007 Dec 3;100(11 A):n10-4. Epub 2007 Aug 31. Review.

PMID:
18047846
8.

Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future.

Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG.

Pharmacol Rev. 2007 Mar;59(1):40-53. Review.

PMID:
17329547
9.

Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach.

Orloff DG.

Am J Cardiol. 2005 Nov 7;96(9A):28K-33K; discussion 34K-35K. Epub 2005 Sep 19.

PMID:
16291011
10.

Homocysteine as a predictive factor for hip fracture in older persons.

Ellenberg SS, Orloff DG, Temple RJ.

N Engl J Med. 2004 Sep 2;351(10):1027-30; author reply 1027-30. No abstract available.

PMID:
15352276
11.

Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.

Isaacsohn JL, Troendle AJ, Orloff DG.

Am J Cardiol. 2004 Jun 3;93(11A):49C-52C. No abstract available.

PMID:
15178516
12.
13.

Anti-lipid trial endpoints.

Orloff DG.

Am J Ther. 1999 Mar;6(2):115-9. Review. No abstract available.

PMID:
10610245
14.

Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies.

Orloff DG, Blazing MA, O'Connor CM.

Am Heart J. 1999 Nov;138(5 Pt 1):S406-12. Review. No abstract available.

PMID:
10539805
15.

Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?

Shepherd J, Olsson AG, Sacks FM, Black DM, Orloff DG, Bilheimer DW.

Am J Cardiol. 1998 Apr 23;81(8A):88F-94F. Review. No abstract available.

PMID:
9604922
16.

Update on the U.S. Food and Drug Administration regulatory approach to over-the-counter cholesterol-lowering drugs.

Orloff DG.

Am J Cardiol. 1998 Apr 23;81(8A):79F. Review. No abstract available.

PMID:
9604919
17.

Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.

Eastman RC, Carson RE, Orloff DG, Cochran CS, Perdue JF, Rechler MM, Lanau F, Roberts CT Jr, Shapiro J, Roth J, et al.

J Clin Invest. 1992 Jun;89(6):1958-63.

18.

A regulated RNA binding protein also possesses aconitase activity.

Kaptain S, Downey WE, Tang C, Philpott C, Haile D, Orloff DG, Harford JB, Rouault TA, Klausner RD.

Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10109-13.

19.

Family of disulphide-linked dimers containing the zeta and eta chains of the T-cell receptor and the gamma chain of Fc receptors.

Orloff DG, Ra CS, Frank SJ, Klausner RD, Kinet JP.

Nature. 1990 Sep 13;347(6289):189-91.

PMID:
2203969
20.

Structural mutations of the T cell receptor zeta chain and its role in T cell activation.

Frank SJ, Niklinska BB, Orloff DG, Merćep M, Ashwell JD, Klausner RD.

Science. 1990 Jul 13;249(4965):174-7.

PMID:
2371564
21.

Role of the zeta chain in the expression of the T cell antigen receptor: genetic reconstitution studies.

Weissman AM, Frank SJ, Orloff DG, Merćep M, Ashwell JD, Klausner RD.

EMBO J. 1989 Dec 1;8(12):3651-6.

22.

Biochemical characterization of the eta chain of the T-cell receptor. A unique subunit related to zeta.

Orloff DG, Frank SJ, Robey FA, Weissman AM, Klausner RD.

J Biol Chem. 1989 Sep 5;264(25):14812-7.

23.

Molecular cloning and chromosomal localization of the human T-cell receptor zeta chain: distinction from the molecular CD3 complex.

Weissman AM, Hou D, Orloff DG, Modi WS, Seuanez H, O'Brien SJ, Klausner RD.

Proc Natl Acad Sci U S A. 1988 Dec;85(24):9709-13.

24.

Effects of damage to the suprachiasmatic area of the anterior hypothalamus on the daily melatonin and cortisol rhythms in the rhesus monkey.

Reppert SM, Perlow MJ, Ungerleider LG, Mishkin M, Tamarkin L, Orloff DG, Hoffman HJ, Klein DC.

J Neurosci. 1981 Dec;1(12):1414-25.

Supplemental Content

Loading ...
Support Center